Evidence mapPaperPMID 41403613Full record

ArticleArchives of medical science : AMS2025

Clinical characteristics and management of hyperlipoproteinemia in patients with chronic coronary heart disease in Slovakia.

Martin Studencan, Daniel Pella, Peter Bramlage, Eva Kaszasova

Abstract read
In one paragraph

Article in Archives of medical science : AMS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Martin StudencanDepartment of Cardiology, Teaching Hospital of J.A. Reiman and Prešov University, Faculty of Health Care, Prešov, Slovak Republic.
Daniel Pella2 Cardiology Clinic East Slovak Institute for CV Diseases (VÚSCH, a.s.), Kosice, Slovak Republic.
Peter BramlageInstitute for Pharmacology and Preventive Medicine, Cloppenburg, Germany.
Eva KaszasovaMerck Sharp & Dohme, Bratislava, Slovak Republic.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: A reduction of low-density lipoprotein (LDL) cholesterol is beneficial for high-risk patients, including patients with previously documented coronary heart disease (CHD). Data on the overall composition, risk profile, and management of these patients are very limited in Slovakia. Material and methods: This cross-sectional multicenter observational study was conducted by cardiologists and internists providing outpatient care at 35 sites across Slovakia between 11/2015 and 01/2016. All patients had documented CHD and fulfilled the very high cardiovascular (CV) risk criteria (ESC recommendations). Results: A total of 349 patients were recruited. Their mean age was 67.8 years, 67.9% were male, 41% had diabetes, and the mean body mass index (BMI) was 29.5 kg/m Conclusions: Patients at high cardiovascular risk in Slovakia are far off the < 1.8 mmol/l LDL-C level recommended for protection from adverse events, and a lower percentage achieve their treatment targets (18.6%) than the mean of other countries globally (29.4%).

Indexed as

coronary heart diseasedyslipidemiaezetimibelow-density lipoprotein cholesterolstatin

Identifiers

PMID41403613
PMCPMC12703591

What Socratic holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.